Pfizer says three-dose regimen of pediatric vaccine effective for ages 6 months to under 5
Pfizer announced on Monday that a third pediatric dose of its vaccine against the coronavirus in children ages 6 months to under five years old provides a strong immune response and is safe. The company cited its clinical trials, in which the pediatric dose – which is one-tenth of the dose given to adults – showed an efficacy of 80.3% in preliminary analyses. Pfizer said it would submit the new data to the US Food and Drug Administration in a bid to get the FDA’s approval for a three-shot regimen of the pediatric dose for the young age group.
Sign Up for Mideast Daily News
Wake up to the Trusted Mideast News source
By subscribing, you agree to The Media Line terms of use and privacy policy.